Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/HP.0000000000000215 | DOI Listing |
J Neurol
December 2024
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Objective: Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS).
Methods: In a cohort study of 270 ALS patients diagnosed from April 2014 to May 2021 in Stockholm, Sweden, we examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis. Summary variables from exploratory factor analysis (EFA) assessed the markers' collective impact on survival.
Nat Commun
September 2024
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Arch Dis Child Fetal Neonatal Ed
September 2024
Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, California, USA.
Objective: To examine whether changes in survival without moderate or severe neurodevelopmental impairment (NDI) at 18-26 months' corrected age from 1999 to 2018 differed between male and female infants.
Design: This retrospective cohort study used data from the NICHD Neonatal Research Network hospitals. Robust Poisson regression models were used to estimate adjusted relative risks (aRRs) and 95% CIs for survival without moderate or severe NDI between males and females.
Arthritis Res Ther
September 2024
New York University Grossman School of Medicine, New York, NY, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!